Sponsor pipeline

Accent Therapeutics clinical trial pipeline

Get alerts when Accent Therapeutics's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-21

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

  1. Notable

    ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy · Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

    Primary endpoint(s) modified

    Also in this update: Phase changed: Phase 1 → Phase 1/2; Enrollment increased: 90 → 218 participants

    Accent TherapeuticsPhase 1/2 NCT06799065 Registry history of NCT06799065 on ClinicalTrials.gov (opens the registry)

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2
1

Disease areas by active trials

Get alerts when Accent Therapeutics's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free